NCT04230473View on ClinicalTrials.gov

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 13, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

November 1, 2022

Conditions
Relapsed or Refractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

single dose of CNCT19

"Dose A: 0.25 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"

Trial Locations (2)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Unknown

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

Juventas Cell Therapy Ltd.

INDUSTRY

NCT04230473 - A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter